Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 89,571

Document Document Title
WO/2018/011578A1
This invention relates to a process for the preparation of Form B of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide. Also disclosed herein is Form B of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopro...  
WO/2018/011681A1
Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, a...  
WO/2018/011169A1
The invention relates to compounds of general formula (I) having pharmacological activity towards the sigma receptor, for use in the prevention and/or treatment of post-herpetic pain.  
WO/2018/011419A2
The invention relates to a uronic acid monomer for use in the treatment of immune system disturbances, inflammatory diseases, kidney diseases, allergies and neurodegenerative diseases, wherein the uronic acid monomer is α-L-guluronic ac...  
WO/2018/011746A1
The present invention provides compounds which are modulators of RORγ and their use for the treatment of diseases or conditions mediated by RORγ. Further, the present invention relates to processes of preparing such compounds, their ta...  
WO/2018/011747A1
The present invention provides compounds which are modulators of RORγ and their use for the treatment of diseases or conditions mediated by RORγ. Further, the present invention relates to processes of preparing such compounds, their ta...  
WO/2018/011416A1
The invention relates to a uronic acid monomer for use in a method for treating Alzheimer's disease, cancer, disorders caused by oxidative stress, a viral disease, migraine, or diabetes, wherein the uronic acid monomer is β-D-mannuronic...  
WO/2018/011579A1
This invention relates to a process for the preparation of Form A of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide. Also disclosed herein is Form A of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopro...  
WO/2018/007957A1
The present invention refers to novel thiazolo[5,4-d]pyrimidine derivatives that are inverse agonists of the adenosine A2A receptor, to a process for their preparation, to the pharmaceutical compositions containing them and to their use ...  
WO/2018/009854A1
The present invention relates to a compound of the formula: where n, R1 and R2 are those defined herein. The present invention also relates to use of a compound of Formula 1 in treating a clinical condition associated with fibrotic disor...  
WO/2018/007920A1
An antagonist of Neurokinin-1 receptor (NKIR), or its ligand Substance P (SP), for use in the treatment of bacterial infections, in particular acute cystitis, or for the management of pain related to the bacterial infection. Compositions...  
WO/2018/008569A1
Provided is an industrially advantageous method for producing a compound (1), specifically a compound (1) in an amorphous form. A method for producing a calcium salt of a 1, 5-benzodiazepine compound represented by formula (1), which is ...  
WO/2018/008749A1
A nucleic acid which can inhibit expression of the MEX3B gene with low cytotoxicity as a side effect, an MEX3B gene expression inhibitor which contains said nucleic acid, a method for inhibiting MEX3B gene expression, and a prophylactic ...  
WO/2018/005685A1
This invention relates to compositions for reducing levels of arachidonic acid (omega-6) found at the cellular level in tissue after surgery, wherein the composition consists of an effective amount of a single fatty acid. In certain embo...  
WO/2018/003962A1
2- (Piperidin-1-yl) pyrimidin-4 (3H) -ones characterized by having a 1,8-diazaspiro [4.5] deca-3-ene, 1-oxa-8-azaspiro [4.5] deca-3-ene, 2,8-diazaspiro [4.5] deca-3-ene, 2-oxa-8-azaspiro [4.5] deca-3-ene, 2,9-diazaspiro [5.5] undeca-3-en...  
WO/2018/002144A1
The present invention relates to compositions comprising: a) a Vitis vinifera extract in free form or in the form of a complex with phospholipids, or a Punica granatum extract; and b) a lipophilic extract of Zingiber officinale; and c) a...  
WO/2018/005848A1
Methods of use, formulations, and devices for delivering therapeutic drugs locally to the region of the spleen are described herein. A method for treating sepsis and other inflammatory disease conditions can include inserting a drug deli...  
WO/2018/001331A1
The present invention relates to an imidazopyridinamine phenyl derivative, pharmaceutically acceptable salt thereof, hydrate or metabolite formed by metabolizing in any form, and use thereof in the preparation of a medicament for prevent...  
WO/2018/006077A1
The invention provides novel chemical compounds useful for treating pain or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.  
WO/2018/003857A1
Provided is a curcumine preparation which is highly water soluble, is capable of maintaining a sufficiently high blood concentration of free curcumine and capable of effectively obtaining the pharmacological effect of curcumine by parent...  
WO/2018/000098A1
A method of treating an inflammatory myopathy includes topically administering to the skin of an individual with the inflammatory myopathy a composition comprising R-salbutamol, a physiologically acceptable derivative thereof, or a pharm...  
WO/2018/001973A1
The present invention relates to pyrazole derivatives of formula (I) having pharmacological activity towards the α2δ subunit, in particular the α2δ-1 subunit, of the voltage-gated calcium channel, in particular having dual pharmacolo...  
WO/2018/001997A1
The present invention relates to calcium salts of (S)-2-(diphenylacetyl)-1, 2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in crystalline form and to a process for producing calcium salts of (S)-2-(diphenylac...  
WO/2018/004379A1
The invention relates to the chemical and pharmaceutical industry and concerns a novel pharmaceutical composition in capsule form for the treatment of joint diseases such as arthritis, acute osteoarthritis, and chronic polyarthritis, inc...  
WO/2018/004498A1
The present invention provides a pharmaceutical composition comprising at least one NSAIA that selectively inhibits COX-2 in combination with at least one H2 receptor antagonist in a single unit pharmaceutical dosage form. Pharmaceutical...  
WO/2018/003867A1
The present invention provides a method for producing a compound represented by formula (I), which comprises a step for obtaining a compound represented by formula (I) by reacting a compound represented by formula (II) and an alkali meta...  
WO/2018/005435A1
The invention relates to 4,6-diaminoquinazoline derivatives of formula I which are modulators of the Cot (cancer Osaka thyroid) kinase, also known as MAP3K8, EST or Tlp-2, and their use for treating e.g. cancer, diabetes and inflammatory...  
WO/2018/002219A1
Fused aromatic bicyclic substituted 5-(2-amino-4-pyrimidinyl)- cyanoindoline derivatives (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK - also known as MAP3K14) useful...  
WO/2017/220050A2
Disclosed are an azithromycin pharmaceutical composition and a medical use thereof for cough relief. The azithromycin pharmaceutical composition contains azithromycin and a natural product compound (I) separated from dried rhizoma arisae...  
WO/2017/221270A1
A modified bile acid-drug conjugate nanoparticle of formula R-L1-BA-L2-D or pharmaceutically acceptable salts thereof; wherein R is natural, synthetic or modified phospholipid head group,polyethylene glycol or poloxamer class of polyols,...  
WO/2017/220045A1
A Chinese medicine composition treating sprains and contusions, said composition comprising an oral Chinese medicine composition and an external application Chinese medicine composition. The oral Chinese medicine composition components a...  
WO/2017/220041A2
Disclosed are a bezafibrate pharmaceutical composition and an application thereof in rheumatoid arthritis. The bezafibrate pharmaceutical composition contains bezafibrate and a natural product compound (I) separated from dried clove buds...  
WO/2017/219935A1
The present invention discloses a biaryl urea RORγt inhibitor, and specifically relates to a biaryl urea derivative, as represented by formula I, with an RORγt inhibiting activity, and a manufacturing method thereof, and a pharmaceutic...  
WO/2017/219509A1
Disclosed are a quinoid chalcone and flavonol conjugate having an anti-tumor activity and an anti-inflammatory activity and a preparation method therefor. Analyses on wave spectrum and mass spectrum data show that a compound (formula I) ...  
WO/2017/219510A1
A quinoid chalcone c-glycoside dimer compound having an anti-tumor activity and an anti-inflammatory activity and a method for preparing same. The compound is a quinoid chalcone c-glycoside dimer compound separated from Carthamus tinctor...  
WO/2017/220048A2
Disclosed is a formulation treating scalding, reducing inflammation and relieving pain, said formulation comprising an external application formulation and an oral formulation. The external application formulation comprises a paste formu...  
WO/2017/219081A1
This invention relates to peptides and their use for modulating sodium channels. More particularly, the present invention relates to peptides from the venom of the tarantula Pamphobeteus nigricolor and their use in methods of inhibiting ...  
WO/2017/220517A1
The invention relates to a compound of formula (I) wherein R1 to R4 and n are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2017/220046A2
Disclosed is a formulation treating rheumatoid osteomyelitis, said formulation comprising an oral formulation and an external application formulation. The oral formulation has the following components by gram: 5-10 grams of poria, 5-10 g...  
WO/2017/221879A1
The present invention addresses the problem of providing: a trophic factor release agent which makes it possible to increase the quantity of a trophic factor released from cells in a cell transplantation therapy or the like; and an infla...  
WO/2017/220052A2
Disclosed is a formulation treating rheumatoid bone pain, said formulation comprising oral formulation and external heat treatment components. The oral formulation components are as follows, by gram: 1-10 grams of poria, 1-10 grams of ra...  
WO/2017/220047A2
Disclosed is a formulation treating joint ache, said formulation comprising oral formulation and external heat treatment components. The oral formulation components are as follows, by gram: 1-10 grams of poria, 1-10 grams of radix astrag...  
WO/2017/220708A1
The present invention relates to the use of carotenoids, in particular a microbial carotenoid compound of formula I, such as methyl-glycosyl-apo-8'-lycopenoate or glycosyl-apo-8'-lycopene, for restoring and/or maintaining a health-benefi...  
WO/2017/215524A1
Provided are an anti-human IL-17A monoclonal antibody, and a preparation method and a use thereof. The anti-human IL-17A monoclonal antibody can specifically bind to human IL-17A and has a good effect for inhibiting the secretion of infl...  
WO/2017/218551A1
The present disclosure provides a method of treating a neurodegenerative disorder, the method comprising administering a DNA methyltransferase inhibitor.  
WO/2017/215588A1
Provided is a dihydropyrazole azepine compound serving as an Akt inhibitor; specifically disclosed is a compound as represented by formula (1) or a pharmaceutically acceptable salt thereof.  
WO/2017/216362A1
Described are methods for producing cannabinoid prodrugs using enzyme-catalysed synthesis / chemical modifications as well as methods for formulating such prodrugs in a pharmaceutically acceptable form and their use as therapeutic agents...  
WO/2017/218330A1
The present disclosure relates generally to compounds (I) which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment...  
WO/2017/218950A1
The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease o...  
WO/2017/217556A1
The purpose of the present invention is to provide a medicine for preventing or treating TGFβ-related diseases by inhibiting signal transduction of TGFβ. Provided are: a TGFβ inhibitor that contains, as an active ingredient, the REIC/...  

Matches 1 - 50 out of 89,571